Amycretin led to a 1.8 reduction in HbA1c levels in the Phase II type 2 diabetes trial.

While type 1 and type 2 diabetes typically occupy distinct places in healthcare, research is showing an increase of patients ...

The Delhi High Court has upheld the Patent Office's refusal to grant Amylin Pharmaceuticals and AstraZeneca Pharmaceuticals a ...

A phase II study has reported that type 2 diabetes patients treated with amycretin-a long-acting investigational GLP-1 and ...

This story was originally published on PharmaVoice. To receive daily news and insights, subscribe to our free daily PharmaVoice newsletter. As drugmakers rush to scrounge up new contenders in the ...

Shares of Novo Nordisk NVO were up 4.7% yesterday, after the company announced positive data from a phase II study evaluating ...

Novo Nordisk said it will now move ahead with a phase 3 programme for both versions of the drug in adults with type 2 ...

Novo Nordisk announces phase 2 clinical trial results of amycretin in people with type 2 diabetes: Bagsværd, Denmark Thursday, November 27, 2025, 13:00 Hrs [IST] Novo Nordisk, a ...

Novo Nordisk is hitting the gas on amycretin development. After posting phase 2 data, the company has decided to run pivotal diabetes trials of an asset that it previously saw primarily as an obesity ...

Trial participants who used eloralintide, a new weight loss medication that, instead of focusing on the hormone GLP-1, ...

The Juvenile Diabetes Research Foundation (JDRF) and Amylin Pharmaceuticals, Inc. announced today that they entered into a research collaboration agreement to provide financial support for a clinical ...

Amycretin also improved participants’ blood sugar levels in positive sign for Danish company’s treatment pipeline ...